SecBot SecBot
PRESS-RELEASE ·Filed May 27, 2026

APGE

Apogee Therapeutics
BULLISH
Impact 8/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The robust Phase 2 data and Blackstone financing significantly de-risk zumilokibart's path to market. Traders should watch for regulatory interactions and Phase 3 initiation in 2H 2026. The pipeline-in-a-product potential (asthma, EoE) adds upside optionality. Monitor upcoming 52-week Part B data and any partnership/out-licensing news.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$77.75
T+0 close · May 27, 2026 · via day close
Latest settled
+73.31%
T+60 · $134.75
Vs SPY
+71.43%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 27 $77.75entry
  2. T+1 · 6mo ago +0.09%α −0.46% · $77.82
  3. T+5 · 6mo ago +1.23%α +0.03% · $78.71
  4. T+20 · 5mo ago +70.65%α +72.55% · $132.68
  5. T+60 · 3mo ago +73.31%α +71.43% · $134.75
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Apogee Therapeutics announced positive 16-week Phase 2 APEX Part B data for zumilokibart in moderate-to-severe atopic dermatitis, meeting primary and secondary endpoints with high statistical significance. The mid-dose achieved 65.9% EASI-75 (41.9% placebo-adjusted) and a favorable safety profile, supporting advancement into Phase 3 trials in 2H 2026. A strategic financing collaboration with Blackstone Life Sciences was also announced, expected to fund through commercialization.

Key Facts

  • Phase 2 APEX Part B met primary endpoint: mid-dose zumilokibart achieved 65.9% EASI-75 vs 23.4% placebo (p<0.001).
  • Key secondary endpoints met: IGA 0/1 46.0% vs 10.9%, EASI-90 47.4% vs 9.3%, I-NRS ≥4 50.5% vs 13.9% (all p<0.001).
  • Very Low Disease Activity (vLDA) achieved in 20.6% of mid-dose patients vs 4.5% placebo (p<0.01).
  • Safety profile consistent with class; conjunctivitis rate for mid-dose was 10.6% vs 20.7% for high dose.
  • Company plans to initiate Phase 3 ADventure trials in AD in 2H 2026, Phase 2b ASPIRE in asthma in 1H 2027, and Phase 2a ELEVATE in EoE in 2H 2026.
  • Strategic financing collaboration with Blackstone Life Sciences announced to fund through commercialization.
  • Mid-dose selected for Phase 3 based on best clinical activity and tolerability.

Financial Impact

Not disclosed; financing collaboration with Blackstone Life Sciences expected to fund through commercialization of zumilokibart in AD, asthma, and EoE.

pipeline valuecash runwaycommercialization timeline

Risk Factors

  • Phase 3 trials may fail to replicate Phase 2 efficacy or safety results.
  • Regulatory interactions could delay or alter Phase 3 trial design.
  • Competition from existing IL-13/IL-4Rα biologics (e.g., dupilumab) and emerging therapies.
  • Dependence on Blackstone financing terms and potential dilution if additional capital needed.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
83% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3301719

Track record

31 reports on APGE

Performance horizon

8 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 11 of 12 went positive at some point.

Filters
  1. Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
  2. Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
  3. Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
  4. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
  5. Aug 10, 202614w ago 8-K Bullish 8/10 No price data
  6. Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
  7. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
  8. Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
  9. Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
  10. Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
Showing 10 of 31

US Market Status

Market Closed · Opens Wed (11h 19m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 27, 2026